HANALL BIOPHARMA CO., LTD.

Other languages Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
35,800 ^KRW	-1.10%		-4.02%	-19.19%

May. 03	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
Mar. 06	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	May. 03
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	22-10-11
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	22-10-04
Hanall Biopharma Co.,Ltd announces an Equity Buyback for 543,479 shares.	22-03-10
Hanall Biopharma Co.,Ltd authorizes a Buyback Plan.	22-03-09
Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021	21-07-29
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	21-05-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer